- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Aventis Streamlines R&D
Pharmaceutical Executive
Aventis announced plans to cut R&D costs by spinning out a stake in one of its research units. The private equity house Warburg Pincus will invest 60 million euro in ProSkelia, taking a 58 percent share.
Aventis announced plans to cut R&D costs by spinning out a stake in one of its research units. The private equity house Warburg Pincus will invest 60 million euro in ProSkelia, taking a 58 percent share. Aventis will retain the other 42 percent. ProSkelia, based in Romainville, near Paris, France, special-izes in early-stage research into treatments for bone disease.
Aventis also intends to spin off its gene therapy unit, Gencell, but it has yet to find a partner that is prepared to meet its valuation. Attempts to reduce research cash burn follow Aventis' discontinuation of trials for two of the company's pipeline compounds. Development of the ACE/NEP (angiotensin con-verting enzyme/neutral endopeptidase) inhibitor M100,240 for the treatment of hypertension was stopped after a Phase II clinical trial yielded disappointing results. Aventis says it intends to examine the drug's possibilities in other therapeutic uses.
It has also terminated a co-development agreement with ViroPharma of Exton, Penn-sylvania, for the antiviral agent Picovir (pleconaril), intended to treat the common cold. FDA issued a non-approvable letter for it in May.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
